1,931 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by Charter Oak Capital Management LLC

Charter Oak Capital Management LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 1,931 shares of the biopharmaceutical company’s stock, valued at approximately $216,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Redwood Financial Network Corp grew its position in shares of Gilead Sciences by 4.0% in the fourth quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 98 shares during the last quarter. Nicolet Advisory Services LLC grew its position in shares of Gilead Sciences by 2.9% in the fourth quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company’s stock valued at $322,000 after purchasing an additional 100 shares during the last quarter. Peak Financial Advisors LLC grew its position in shares of Gilead Sciences by 1.7% in the first quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company’s stock valued at $677,000 after purchasing an additional 100 shares during the last quarter. Perkins Coie Trust Co grew its position in shares of Gilead Sciences by 2.6% in the first quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company’s stock valued at $435,000 after purchasing an additional 100 shares during the last quarter. Finally, CFO4Life Group LLC grew its position in shares of Gilead Sciences by 2.7% in the fourth quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company’s stock valued at $394,000 after purchasing an additional 112 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on GILD. Morgan Stanley upped their target price on Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research report on Friday, April 25th. Bank of America upped their target price on Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Piper Sandler boosted their price target on Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Royal Bank of Canada boosted their price target on Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price target for the company from $80.00 to $120.00 in a research note on Tuesday, February 18th. Nine equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $110.55.

Gilead Sciences Stock Up 1.8%

NASDAQ GILD opened at $112.46 on Monday. The business has a fifty day moving average price of $105.39 and a two-hundred day moving average price of $101.64. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a fifty-two week low of $62.69 and a fifty-two week high of $119.96. The stock has a market capitalization of $139.89 billion, a PE ratio of 303.95, a PEG ratio of 0.71 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm had revenue of $6.67 billion during the quarter, compared to analysts’ expectations of $6.77 billion. During the same period in the prior year, the company earned ($1.32) earnings per share. The company’s quarterly revenue was down .3% on a year-over-year basis. Equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.81%. The ex-dividend date is Friday, June 13th. Gilead Sciences’s payout ratio is 66.53%.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total value of $266,000.00. Following the completion of the transaction, the chief financial officer now directly owns 168,174 shares in the company, valued at approximately $17,893,713.60. This represents a 1.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Friday, May 30th. The shares were sold at an average price of $110.42, for a total value of $1,104,200.00. Following the completion of the transaction, the chief executive officer now owns 620,268 shares of the company’s stock, valued at $68,489,992.56. The trade was a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 43,000 shares of company stock worth $4,630,310. Insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.